黏蛋白-1和细胞角蛋白-20在食管癌中的表达及意义

Objective To investigate the expressions and clinical significances of MUC1-mRNA and CK20-mRNA in peripheral blood of esophageal cancer patients.Methods MUC1-mRNA and CK20-mRNA were detected in 53 patients with esophageal cancer,10 patients with esophageal benign tumor and 20 healthy volunteers by RT-PCR technique.Results The expressions of MUC1-mRNA,CK20-mRNA and combining group were 35.85 % (19/53),49.06 % (26/53) and 62.26 % (36/53) in peripheral blood of 53 esophageal cancer patients.In control group,there was no expression of MUC1-mRNA and CK20-mRNA in peripheral blood of 10 patients with benign esophageal disease and 20 healthy volunteers.The positive rate increased by combining test(x2 =11.0228,P ＜0.05).Conclusion MUC1-mRNA and CK20-mRNA might be specific and sensitive markers to detect circulating tumor cells in peripheral blood and their expressions are closely related to TNM stages of the esophageal cancer patients.The combining test might be of high value of the diagnosis of micrometastasis.     

黏蛋白-1和细胞角蛋白-20在食管癌中的表达及意义

Objective To investigate the expressions and clinical significances of MUC1-mRNA and CK20-mRNA in peripheral blood of esophageal cancer patients.Methods MUC1-mRNA and CK20-mRNA were detected in 53 patients with esophageal cancer,10 patients with esophageal benign tumor and 20 healthy volunteers by RT-PCR technique.Results The expressions of MUC1-mRNA,CK20-mRNA and combining group were 35.85 % (19/53),49.06 % (26/53) and 62.26 % (36/53) in peripheral blood of 53 esophageal cancer patients.In control group,there was no expression of MUC1-mRNA and CK20-mRNA in peripheral blood of 10 patients with benign esophageal disease and 20 healthy volunteers.The positive rate increased by combining test(x2 =11.0228,P ＜0.05).Conclusion MUC1-mRNA and CK20-mRNA might be specific and sensitive markers to detect circulating tumor cells in peripheral blood and their expressions are closely related to TNM stages of the esophageal cancer patients.The combining test might be of high value of the diagnosis of micrometastasis.     

Expression of sIL-2R before and after chemotherapy in patients with breast cancer

Objective:To investigate the difference of peripheral blood sIL-2R before and after chemotherapy in breast cancer patients,and evaluate the clinical value of the sIL-2R in breast cancer's diagnosis and therapy.Methods:The peripheral blood sIL-2R levels of the breast cancer patients with or without chemotherapy were detected by ELISA.The healthy persons were made as the control group.Results:The slL-2R levels of the breast cancer patients were higher than that of the control group(P＜0.05);the slL-2R's levels in Ⅰ～Ⅱ stage breast cancer were lower than that in Ⅲ～Ⅳ stag e breast cancer (P＜0.05);the sIL-2R levels of the patients before chemotherapy were higher than that of the patients undergone chemotherapy(P＜0.05);The level of the patient with chemotherapy was still higher than that of the control group(P＜0.05);the sIL-2R levels of the patients whose chemotherapies were noneffective were higher than that of the patients received effective chemotherapies(P＜0.05).There was no significant difference between the group with ER( )or PR( )and the group with ER(-)or PR(-)(P＞0.05).Conclusion:The breast cancer patients have the high slL-2R levels.There is a close relationship between the cancer incidence and the patients,immune situation.The level of slL-2R could be a clinical index which Can be used for evaluating the cancer degree,because the higher levels of slL-2R can indicate that the immune ability of patient is worse.There is a significant difference between the slL-2R levels of the patients before chemotherapy and that of the patients undergone chemotherapy.     

ACETYLATOR PHENOTYPE AND ITS RELATIONSHIP TO BREAST TUMOR

The patterns of acetylator phenotypes has been determined in 102 women with breast tumors, including 25 with benign breast disease and 77 with breast cancer, and compared to that in 59 healthy controls. There was significant increase (16.2%) of rapid acetylators in 77 patients with breast cancer, P<0.05. As a result of the effect of therapy on the rate of acetylation, it was found that in 39 patients with breast cancer the level of acetylation was decreased after mastectomy. The difference of percentage acetylation between preoperation and post-operation was statistically significant, P<0.05. A similar change in 8 patients with breast cancer could be observed after chemotherapy, P<0.01. The results obtained in the present study indicated that there was a significant association between rapid phcnotype and breast cancer of women. The mastectomy or inhibition of tumor growth may bring about a decrease in the level of acetylation.     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

Determination of PDCD5 in peripheral blood serum of cancer patients

Objective:Programmed cell death 5 (PDCD5) is an apoptosis related gene and plays an important role in the pathogenesis and development of cancer.Whether PDCD5 is present in peripheral blood serum has not been reported.The aim of this study is to determine the contents of PDCD5 protein in peripheral blood serum of cancer patients,as well as normal subjects.Methods:ELISA was used to detect the serum PDCD5 concentrations in 100 normal persons,83 patients with breast cancer,74 patients with gastrointestinal tract cancer and 41 patients with lung cancer.The results were statistically analyzed and discussed.Results:PDCD5 could be detected in peripheral blood serum in both normal subjects and cancer patients.The serum PDCD5 contents in normal persons ranged from 3.8 to 6.1 ng/ml with a median of 4.70±0.68 ng/ml.For cancer patients the PDCD5 levels were 4.59±0.90,4.79±1.14 and 10.43±22.34 ng/ml for breast cancer,gastrointestinal cancer and lung cancer patients respectively.There was no statistically significant difference between the serum PDCD5 concentrations of normal persons and cancer patients.Conclusion:PDCD5 is present in peripheral blood.The PDCD5 levels in cancer patients are not statistically different from that of normal persons,though decreased expression of PDCD5 in malignant tissues has been found.     

人乳腺癌外周血中hMAM mRNA表达及临床意义

目的：研究人乳腺癌外周血珠蛋白（hMAM）mRNA表达及临床意义。方法：应用nested-RT-PCR技术检测50例乳腺癌外周血hMAM mRNA的表达和化疗前后外周血hMAM mRNA的变化,并取20例乳腺纤维腺瘤、10例健康志愿者作阴性对照。结果：50例乳腺癌外周血hMAM mRNA的阳性表达率为34.0%;20例乳腺纤维腺瘤及10例健康志愿者外周血中均未检出hMAM mRNA的表达。hMAM mRNA的阳性与淋巴结转移状况、肿瘤TNM分期之间差异有统计学意义;50例乳腺癌化疗前检测17例hMAM mRNA阳性,化疗2～3周期后13例hMAM mRNA转为阴性,转阴率76.5%（13/17）,化疗前后差异非常显著（P=0.001）。结论：乳腺癌外周血中hMAM mRNA表达可以反映术后化疗对乳腺癌血液微转移的影响,有望成为乳腺癌血道微转移标志物和一个重要的预后指标。     

hMAM mRNA表达情况与乳腺癌的关系

目的 探讨人乳腺珠蛋白(hMAM)mRNA在乳腺癌患者外周血中的表达情况及意义.方法 选取87例乳腺癌患者、70例乳腺良性肿瘤患者和50例健康志愿者,采用巢式-逆转录-聚合酶链反应检测其外周血hMAM mRNA的表达水平.结果 乳腺癌患者的外周血hMAM mRNA阳性率为54.02%,高于乳腺良性肿瘤患者的1.43%和健康志愿者的0,差异均有统计学意义(P﹤0.05);乳腺良性肿瘤患者和健康志愿者的外周血hMAM mRNA阳性率比较,差异无统计学意义(P﹥0.05).Ⅲ~Ⅳ期、有淋巴结转移的乳腺癌患者的hMAM mRNA阳性率高于Ⅰ~Ⅱ期和无淋巴结转移的患者(P﹤0.05).乳腺癌患者化疗后的外周血hMAM mRNA阳性率为18.39%,低于化疗前的54.02%(P﹤0.05).结论 乳腺癌患者外周血hMAM mRNA的阳性表达与TNM分期和淋巴结转移情况有关,可为临床诊断和预后判断提供依据.     

乳腺癌患者外周血hMAM及SBEM检测及其临床意义

目的研究乳腺癌患者外周血人乳腺珠蛋白（hMAM）及乳腺上皮粘蛋白（SBEM）的表达及临床意义。方法应用逆转录聚合酶链反应（RT-PCR）技术检测58例乳腺癌患者外周血hMAM mRNA及SBEM mRNA的表达，并用健康志愿者及乳腺良性肿瘤患者各10例作为对照。结果hMAM及SBEM在58例乳腺癌患者外周血的阳性表达率分别为34.5%、25.9%，乳腺良性肿瘤和正常对照均无阳性表达，两者的阳性表达与患者的临床分期显著相关（P〈0.05），两者联合检测的总阳性率为41.4%（24/58），与单一标志物相比缺乏统计学意义。结论hMAM及SBEM特异性表达于乳腺癌外周血，可作为检测乳腺癌外周血肿瘤细胞标志物，并有可能在乳腺癌微转移诊断和预后判断中具有重要意义。     

乳腺癌患者外周血中CEA mRNA表达的检测及临床意义

目的探讨RT—PCR法检测乳腺癌患者外周血中的CEA mRNA表达的情况及在乳腺癌外周血微转移诊断中的应用。方法采用RT—PCR法,检测46例乳腺癌患者外周血中CEA mRNA表达情况,以良性乳腺疾病患者及健康志愿者外周血标本作为对照。结果46例乳腺癌患者外周血中CEA mRNA阳性率为32．6％。对照组中CEA mRNA表达均为阴性。CEA mRNA的阳性表达与患者的TNM分期、腋淋巴结状况差异有统计学意义（P〈0．05）,而与患者的年龄、原发肿瘤大小、病理类型以及激素受体状况等差异均无统计学意义（P〉0．05）。结论CEA mRNA可作为标志物来检测乳腺癌患者外周血中微转移,有助于指导临床治疗及判断预后。     

乳腺癌患者外周血中PIP mRNA检测的临床意义

目的:探讨泌乳素诱导蛋白(PIP)mRNA作为标志检测乳腺癌患者外周血中微转移的可能性。方法:用逆转录-聚合酶链反应(RT-PCR)法,检测69例乳腺癌患者外周血中PIPmRNA表达情况,另抽取28例乳腺良性疾病患者和10例健康志愿者外周血标本作为对照组。结果:69例乳腺癌患者外周血中PIPmRNA有21例表达,阳性率为30.4%,对照组中PIPmRNA表达均为阴性。两组比较差异有统计学意义,P<0.05。PIPmRNA的阳性表达与患者的淋巴结转移状况差异有统计学意义,P<0.05;而与患者的年龄、原发肿瘤大小、分期、病理类型、ER、PR等差异均无统计学意义,P>0.05。结论:PIPmRNA可能作为标志来检测乳腺患者外周血中微转移。     

hMAM mRNA和CEA mRNA RT-PCR检测乳腺癌外周血微转移

目的:应用RT-PCR法检测乳腺癌患者外周血中的hMAM mRNA和CEA mRNA表达情况.方法:用RT-PCR法,检测52例乳腺癌患者外周血中hMAM mRNA和CEA mRNA的表达情况,另抽取28例乳腺良性疾病患者和10例健康志愿者外周血标本作为对照.结果:52例乳腺癌患者外周血中hMAM mRNA和CEA mRNA的阳性率分别为30.8%、34.6%.28倒乳腺良性疾病患者和10例健康志愿者外周血中hMAM mRNA、CEA mRNA表达均为阴性.二者的阳性表达与患者的腋淋巴结状况、TNM分期差异均有显著性意义(P＜0.05),而与患者的年龄、原发肿瘤大小、病理类型以及激素受体状况等差异均无显著性(P＞0.05).结论:hMAM mRNA、CEA mRNA均可作为标志物来检测乳腺癌患者外周血中微转移,联合检测可增加外周血中循环肿瘤细胞的检出率.     

新辅助化疗前后乳腺癌患者外周血细胞角蛋白19表达变化及其临床意义

目的探讨细胞角蛋白（CK）19在乳腺癌新辅助化疗前后表达的变化及其临床意义。方法采用实时定量RT-PCR技术检测86例乳腺癌患者新辅助化疗前后外周血CK19 mRNA的表达变化,将30例乳腺良性疾病患者和20例健康体检志愿者作为对照。对非正态分布或方差不齐的数据采用Wilcoxon非参数秩和检验,用中位数±百分位数之差[M（Q_R）]表示,计数资料组间采用χ~2检验。结果新辅助化疗前乳腺癌患者外周血中CK19 mRNA阳性表达率为32.56%（28/86）,与腋窝淋巴结转移、临床分期有关（分别P〈0.001）;而新辅助化疗后阳性表达率为13.95%（12/86）,化疗前后CK19mRNA表达差异具有统计学意义（P=0.004）;新辅助化疗后CK19 mRNA阳性表达的患者中,57.14%（16/28）获得临床完全缓解成部分缓解,低于CK19 mRNA阴性患者的93.10%（54/58）,差异有统计学意义（P〈0.001）,这提示CK19 mNRA表达水平变化可能与新辅助化疗疗效有关。结论 CK19可作为新辅助化疗疗效判定的早期预测指标之一。